Main results
Four trials reported on 7095 women. The women were highly selected: tumours were node negative and 89.8% were smaller than 3 cm. Where the breast size was known, 87% had small or medium breasts. The studies were of low to medium quality. Unconventional fractionation (delivering radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not affect: (1) local recurrence risk ratio (RR) 0.97 (95% CI 0.76 to 1.22, P = 0.78), (2) breast appearance RR 1.17 (95% CI 0.98 to 1.39, P = 0.09), (3) survival at five years RR 0.89 (95% CI 0.77 to 1.04, P = 0.16). Acute skin toxicity was decreased with unconventional fractionation: RR 0.21 (95% CI 0.07 to 0.64, P = 0.007).
Authors' conclusions
Two new studies have been published since the last version of the review, altering our conclusions. We have evidence from four low to medium quality randomised trials that using unconventional fractionation regimens (greater than 2 Gy per fraction) does not affect local recurrence, is associated with decreased acute toxicity and does not seem to affect breast appearance or late toxicity for selected women treated with breast conserving therapy. These are mostly women with node negative tumours smaller than 3 cm and negative pathological margins. Long-term follow up (> 5 years) is available for a small proportion of the patients randomised. Longer follow up is required for a more complete assessment of the effect of altered fractionation.
P L A I N L A N G U A G E S U M M A R Y

Fraction size in radiation treatment for breast conservation in early breast cancer
Breast cancer is an important disease for women, with one in eight women in the United States and Australia and one in nine women in the United Kingdom being diagnosed with the condition by age 85 years. Breast conserving therapy (removing the tumour but keeping an intact breast) has proven to be as effective as mastectomy (removing the breast tissue) in terms of survival for women with cancer confined to the breast (or the local lymph nodes, or both), as long as a five to six-week course of radiation therapy is delivered. This involves 25 to 30 visits to a radiation oncology department. Without radiation therapy after breast conserving surgery there is a significant risk of breast cancer returning in the breast (local recurrence) in as many as 30 to 40 women per 100. Furthermore, for every local recurrence avoided with radiation, one death is avoided at 15 years. Many women prefer breast conservation which has resulted in an increased demand for radiation services. Giving fewer radiation treatments (fractions) would be beneficial to women if this has the same effect on tumour control and survival and cosmetic outcome. In order to reduce the number of treatments, the radiation dose delivered per fraction is increased. This may also reduce demand on radiation resources and be more convenient for women.
Four trials, involving 7095 women, were included in this review. Local recurrence was not significantly different for women having fewer treatments. Breast appearance was not significantly different for women undergoing fewer treatments. Survival was not altered by having fewer treatments and there was no significant difference in late skin toxicity or radiation toxicity. Acute skin toxicity is decreased with fewer treatments. Most of the women in the trials (89.8%) had tumours less than 3 cm in size, all had complete removal of the tumour on pathology and 79% had no evidence of cancer in their lymph nodes. Where the breast size was known, 87% had small or medium breasts. This review indicates that for women who fit these criteria, using fewer radiation treatments after tumour removal is a safe and effective option. Long-term follow up (> 5 years) is available for a small proportion of the total number of patients randomised. Ongoing follow up is required for a more complete assessment of the impact of larger than standard fraction size on local recurrence rates, toxicity and breast appearance.
B A C K G R O U N D Description of the condition
This review is an update of a review previously published in The Cochrane Database of Systematic Reviews (Issue 3, 2008) on fraction size in radiation treatment for breast conservation in early breast cancer. Breast cancer is the most common cancer diagnosed in women and the second most common cause of cancer death in women. The lifetime risk to age 85 years of being diagnosed with breast cancer for women living in Australia and the United States is one in eight, and one in nine for women living in the United Kingdom (AIHW 2006; ONS 1999; Ries 2004) . A significant change has occurred in the management of women with early breast cancer (cancer confined to the breast and nearby lymph nodes) over the last three decades. Previously most women with early breast cancer underwent removal of the whole breast (mastectomy). Evidence from several randomised controlled trials (Fisher 1989; Veronesi 1990 ) and a meta-analysis of 36 trials (EBCTCG 1995) confirms that long-term overall survival is equivalent using breast conserving treatment compared with mastectomy. Breast conserving treatment comprises removal of the portion of the breast containing the tumour followed by radiation treatment to the remaining breast tissue. Other studies have shown that quality of life is enhanced in women who undergo breast conserving treatment (Al-Ghazal 2000) . Consequently, breast conserving treatment has become the recommended option for women with early breast cancer in many western countries (NBCC 2001; NIH 1991) . Breast conserving surgery now accounts for 70% of breast cancer operations in some series (Chouillet 1994) and, as a result, demand for radiation treatment services has increased. Some health services have struggled to meet this increasing demand because of a shortage of trained personnel and expensive radiation treatment machines (Ash 2000; Mackillop 1994).
Description of the intervention
Radiation following breast conserving surgery involves treatment to the breast with ionising radiation. Typically the radiation is delivered over a period of five to six weeks using a standard 2 Gy (Gray) radiation dose per fraction, in 25 to 30 treatment episodes, to a total dose of 50 to 60 Gy. Recently there has been interest from cancer service providers in shortening the overall treatment time. One method of achieving this is to increase the size of each fraction thereby decreasing the total number of fractions required. For example, case series using 40 Gy in 15 fractions or 36 Gy in 12 fractions have been reported (Ash 2000; Olivotto 1996) . Shorter fractionation schedules have the advantages of using machine and staff time more efficiently and reducing patient inconvenience. Concerns have been raised, however, as to whether shorter fractionation schedules have equivalent outcomes in terms of local tumour control, breast appearance (cosmesis), late toxicity, overall survival and patient satisfaction. The concern with larger fraction sizes is based on radiobiological principles which state that the fraction size is the dominant factor in determining late side effects. The aim of conventional fractionation at 2 Gy per fraction is to decrease the rate of late tissue damage whilst aiming to maximise tumour control with acceptable acute toxicity (Hall 1994). Higher fraction size could lead to increased scarring and retraction of breast tissue as well as skin atrophy (thinning) and telangiectasia (dilated blood vessels).
Why it is important to do this review
The optimal fractionation schedule is not well-established ( Whelan 1993) but evidence from clinical trials suggests that the results of shorter schedules may be equivalent with respect to local control and cosmesis (Whelan 2000; Yarnold 1994) . Published trials to date have been too small to detect differences in cancer recurrence rates reliably. If a shorter fractionation schedule was shown to provide equivalent outcomes for women this could lead to more efficient use of radiation services and more expedient treatment for patients.
O B J E C T I V E S
To determine the effect of altered radiation fraction size on outcomes for women with early breast cancer who have undergone breast conserving surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials were considered for inclusion. We required the comparisons to be unconfounded, that is the treatment given to the intervention and comparator groups could differ only in relation to the fractionation schedule used. Trials where the participants received adjuvant treatment in the form of chemotherapy, monoclonal antibody treatment, or hormonal therapy were eligible providing these treatments were applied equally to all study groups. Published and unpublished studies were eligible.
Types of participants
Women with histologically confirmed early breast cancer who had undergone breast conserving surgery. Early breast cancer is defined as invasive adenocarcinoma restricted to the breast, plus or minus the local lymph nodes, which can be removed surgically (EBCTCG 2002) , that is T1-2, N0-1, M0 (Fleming 1997). Surgery could include lumpectomy, wide local excision, quadrantectomy, or segmental resection; with or without axillary dissection, node sampling, or sentinel node biopsy.
Types of interventions
Postoperative radiation to the breast alone and delivered using conventional fractionation (1.8 to 2 Gy per fraction) versus postoperative radiation to the breast alone at greater than 2 Gy per fraction. In order to compare the differing dose schedules we converted fractionation schedules to biologically equivalent doses (BED). The dose prescribed and the prescription point had to be clearly identified. We specified the dose in accordance with the International Commission on Radiation Units and Measurements (ICRU 50) recommendations with respect to dose, dose specification point and dose per fraction. Where possible, we converted data found in studies into this form.
Types of outcome measures
Primary outcomes
1. Local recurrence in the ipsilateral breast (i.e. the same breast where the cancer had been diagnosed).
2. Appearance or cosmesis (objective and subjective) of the treated breast.
Secondary outcomes
1. Overall survival (time from date of randomisation to death from any cause, or number of deaths from any cause).
2. Toxicity (including acute and late effects of radiation therapy and chemotherapy-related toxicity); individual protocolbased definitions were used.
3. Cancer-specific mortality. 4. Relapse-free survival. 5. Mastectomy rate (following local recurrence). 6. Quality of life (trial-specific instruments). 7. Costs (to women and health services). 
Search methods for identification of studies
Data collection and analysis
Selection of studies
All four original authors checked the titles and abstracts retrieved by the searches. BH did so for the repeated search. Each author independently assessed the full text of all studies we thought relevant to the review with differences being resolved by discussion.
Data extraction and management
Two authors (BH and ML) performed data extraction independently, with disagreements being resolved by discussion. We entered data into START B 2008 , the report presented hazard ratios (HR), number of events in each arm and the randomisation ratio was 1:1, so we used these to derive the log rank statistic (O-E) and its variance (Sydes 2007). For Whelan 2002, data from the curve were presented with numbers at risk, so we used these to derive the log rank statistic (O-E) and its variance (Sydes 2007). For relapse-free survival (Whelan 2002), numbers at risk were given, so we derived the log rank statistic (O-E) and its variance from the survival curves (Sydes 2007).
Assessment of risk of bias in included studies
Two review authors (BH, ML) categorised the risk of bias of each eligible study using the system outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). DF resolved any discrepancies which arose. Risk of bias tables were constructed (constructed by BH, and reviewed by ML), with any discrepancies resolved by discussion for the included studies. We constructed a 'Risk of bias' graph with review authors' judgements about each methodological quality item (presented as percentages across all included studies) (see Figure 1) .
We planned sensitivity analysis on the basis of study quality, which was to be performed with and without trials of low quality to assess the effect of quality on the results. This was not possible with only four included trials.
Measures of treatment effect
Summary statistics for dichotomous measures were presented as risk ratios (RR) with 95% confidence intervals (CI) (Deeks 2003 
Data synthesis (meta-analysis)
We applied the intention-to-treat principle in analysing data from the trials and determined a weighted average treatment effect using the fixed-effect model to combine results (Mantel 1959) 
Subgroup analysis and investigation of heterogeneity
The current version of the review does not contain any subgroup analyses because of the lack of data. However, if sufficient data become available in future updates we may perform subgroup analyses to investigate whether the effects of different radiation fraction schedules differ depending on nodal status, margin status, hormone receptor status, and tumour stage or other factors which may become relevant in the future. We assessed heterogeneity both visually and statistically using the Using these values, we aimed to compare those studies with a BED < 75 and a BED > 75. Brachytherapy (radiation sources applied directly to the body) would be converted to BED using the method of Stitt (Stitt 1992; Yamada 1999). For brachytherapy we recorded data, where possible, in the form of dose, dose specification point, plane of interest (for example at 1 cm from the central plane), mean central dose and peripheral dose.
R E S U L T S Description of studies
We screened a total of 2284 abstracts, and considered 67 papers in full for eligibility. We excluded 48 (see table Characteristics Gy in 25 fractions). The trial was multi-centred with patients recruited from tertiary institutions. This study included 1234 women with node negative, invasive breast cancer who were treated with lumpectomy and had negative pathological margins. Patients with large breasts (defined as a cup size separation of greater than 25 cm, that is the breast measured greater than 25 cm left to right at its widest part) were excluded. The primary outcome measure was local recurrence of invasive breast cancer in the treated breast. The trial reported breast appearance and late radiation toxicity but did not assess costs or quality of life. The five-point Radiation Oncology Group/ EORTC late radiation morbidity scale (Winchester 1992) was used to report skin toxicity (additional Table 2 ). Global cosmetic outcome was assessed by trained clinical trials nurses using the four-point European Organisation for Research and Treatment of Cancer (EORTC) Cosmetic Rating System (additional Table 1 ). 1220/1234(98.8%) of the women in the trial had baseline cosmetic assessment. Cosmetic outcome was assessed in the 735/1220 women with five years follow up at the time of assessment. No women were treated with boosts (extra dose delivered to the tumour bed) (see additional Table 4 ). More detail is available in the table Characteristics of included studies.
The second study (Owen 2006) was a randomised controlled trial comparing three fractionation regimens (39 Gy in 13 fractions, 42.9 Gy in 13 fractions, and 50 Gy in 25 fractions). The trial was multi-centred in a tertiary setting. The study included 1410 women with invasive breast cancer who were treated with breast conserving surgery and had negative pathological margins. The primary outcome measure was late change in breast appearance. Late change in breast appearance was assessed in the 1202 women who had photographs available at baseline and at least a single follow up. Pairs of photographs were available as follows: 1128 at year one, 1004 at year two, 525 at three years, 472 at four years, 765 at five years and 141 at 10 years, i.e. photographic follow up was reported for 63% of women at five years, and 11% at 10 years. The trial reported both cosmesis and late radiation toxicity but did not assess costs or quality of life. Cosmesis (appearance) was assessed clinically in the first 806 women at annual follow-up visits; clinicians used a four-point scale (Additional Table 5 ). We have no evidence that these women were substantially different to the remainder of women in the trial: the reasons that women were not followed were not related to which arm they were randomised to and were not related to whether they had local relapse or late normal tissue side-effects from treatment. Quote: "Reasons for non-availability were explored, and no evidence was observed that this was associated with either the fractionation schedule or to the probability of experiencing future normal tissue event or local relapse (Owen 2006)." The clinical assessment results were dichotomised in the report into fair or poor versus good or excellent (Owen 2006). Of women enrolled, 1051 (75%) were treated with a boost of 14 Gy at 90% in seven fractions. The authors did not report how many women in each arm received a boost. For women with negative margins, if the clinician felt it was appropriate, there was a sub-randomisation to boost or no boost from January 1986 to May 1994. After this, all 687 patients were offered an elective boost (see additional Table 4 ). START A 2008 was a randomised trial comparing three fractionation regimens (41.6 Gy in 13 fractions, 39 Gy in 13 fractions and 50 Gy in 25 fractions). The trial was multi-centred in a tertiary setting. The study included 2236 women with invasive breast cancer, 85% of them were treated with breast conserving surgery, and all had negative pathological margins. The primary outcome measures were loco-regional relapse, normal tissue effects and quality of life. The trial reported cosmesis and late radiation toxicity. Quality of life and economic consequences (which were not defined) will be reported separately for women from 13 centres participating in START A 2008. Late change in breast appearance (photographic) was assessed in the 1055 women who had both a photo at baseline and a follow-up photo. Not all patients had a photo at five years. Those with photos at two and five years were combined when reported, and the authors did not report how many had fiveyear follow up. We have no evidence that these women were substantially different to the remainder of women in the trial. Quote: "There were no associations between score for change in breast appearance (photographic) at two years or patient demographic or treatment characteristics and whether or not the patient had a fiveyear assessment (data not shown)" (START A 2008). For women treated with breast conservation, 771/1269 (61%) of women in the experimental arm and 381/631 (60%) of women in the control arm received a boost of 10 Gy in five fractions using electrons. In total, 1152/1900 (61%) received a boost. Each participating department specified in advance whether patients enrolled from that site would receive radiotherapy boost (see additional Table 4 ). START B 2008 was a randomised trial comparing two fractionation regimens (40 Gy in 15 fractions and 50 Gy in 25 fractions). The trial was multi-centred in a tertiary setting. The study included 2215 women with invasive breast cancer; 2038/2215 (92%) of them were treated with breast conserving surgery, and all had negative pathological margins. The primary outcome measures were loco-regional relapse, normal tissue effects and quality of life. The trial reported cosmesis and late radiation toxicity. Quality of life and economic consequences (which were not defined) will be reported separately. Late change in breast appearance (photographic) was assessed in the 923 women who had both a photo at baseline and a follow-up photo. Not all patients had a photo at five years; those with photos at two and five years were combined when reported and the authors did not report how many had fiveyear follow up. Quote: "There were no associations between score for change in breast appearance (photographic) at two years or patient demographic or treatment characteristics and whether or not the patient had a five-year assessment (data not shown)".(START B 2008). Quote: "We have no evidence that these women were substantially different to the remainder of women in the trial". For women treated with breast conservation, 446/1018 (44%) and 422/1020 (41%) received a 10 Gy on five fraction boost using electrons. In total, 868/2038 (43%) received a boost. Each participating department specified in advance whether patients enrolled from that site would receive radiotherapy boost (see additional  Table 4 ). More detail is available in the table Characteristics of included studies. 
Risk of bias in included studies
Effects of interventions
Four trials enrolling 7095 women were included in the review. In the results presented here, ratios of treatment effects are given such that RRs < 1.0 would indicate a beneficial effect of unconventional fractionation over conventional fractionation (although, as noted below, most of these results were not statistically significant).
Primary outcomes Ipsilateral local recurrence
Overall, 271 local recurrences in 7095 women were reported at five years. 3. Local recurrence at five years using log rank statistic (O-E) and its variance: HR 0.93 (95% CI 0.63 to 1.38, P = 0.72). The test for heterogeneity (I 2 = 56%, P = 0.13) indicates that there is unlikely to be heterogeneity, as the confidence intervals overlap and P value is greater than 0.10 (Analysis 1.3). Data were available from all trials but not in a form which could be combined in analysis. Global cosmetic outcome was reported for 735 women at five years (Whelan 2002). The triallists performed cosmetic assessment on 1220 women at baseline and had complete cosmetic data on 735 women at five years (the time of interest for the outcome). We have no indication that these women were different to the remainder of those randomised. A four-point scale (Aaronson 1988) was used and the results were dichotomised as good or excellent versus poor or fair. These results were reported as percentages at three and five years with the total number of women available for evaluation at each time period; as we did not know the numbers in each arm, we were unable to derive figures from these data. At five years, the percentage of patients with good or excellent global cosmetic outcome was 76.8% in the altered fractionation arm and 77.4% in the conventional fractionation arm (absolute difference -0.6%, 95% CI -6.5% to 5.5%), P value not reported; figures from the text (Whelan 2002). At median follow up of 12 years, the percentage of patients with good or excellent global cosmetic outcome was 70% in the altered fractionation arm and 71% in the conventional arm (absolute difference 1.5%; 95% CI -6.9% to 9.8%, P value not reported); figures from the text (Whelan 2002). Owen 2006 reported breast cosmesis (median follow up of 8.1 years, maximum 15 years) using a four-point scale (see additional  Table 5 ). A total of 806 women (see Description of studies) were assessed and the results were reported for a dichotomous outcome in the report. Of 535 women in the altered fractionation arm, 244 (41.8%) were scored as having a good or excellent result and 106 of 271 (39.1%) in the conventional fractionation arm had a good or excellent result (figures derived from the text): RR 1.17 (95% CI 0.98 to 1.39, P = 0.09). Testing for heterogeneity was not applicable (Analysis 1.5). START A 2008 reported photographic assessment of change in breast appearance for those women treated with breast conserving surgery (median follow up of 6.0 years, maximum 6.2 years) using a three-point scale. A total of 1055 women (see Description of studies) were assessed at a mix of two and five years and were dichotomised into mild or marked change or no change (figures reported from text). For comparison of 41.6 Gy versus 50 Gy: hazard ratio (HR) 1.09 (95% CI 0.85 to 1.40, P = 0.62). For comparison of 39 Gy versus 50 Gy: HR 0.69 (95% CI 0.52 to 0.91, P = 0.01). START B 2008 reported photographic assessment of change in breast appearance for those women treated with breast conserving surgery (median follow up of 5.1 years, maximum 6.0 years) using a three-point scale. A total of 923 women (see Description of studies) were assessed at a mix of two and five years and were dichotomised into mild or marked change or no change (figures reported from text): HR 0.83 (95% CI 0.66 to 1.04, P = 0.06). Owen 2006 reported minimum five-year follow up for any or marked change in breast appearance and found no significant difference between the unconventional and conventional arms for any change: RR 1.01 (95% CI 0.88 to 1.17, P = 0.86) or for marked change: RR 1.24 (95% CI 0.77 to 2.00, P = 0.37). There was no difference in moderate or marked breast distortion between the two trial arms: RR 1.01 (95% CI 0.87 to 1.17, P = 0.90). 
Secondary outcomes
Toxicity
(Including acute and late effects of radiation therapy, and chemotherapy-related toxicity). Individual protocol-based definitions were used. Toxicity and late effects were reported on assessable numbers.
Acute radiation toxicity
Acute radiation toxicity was significantly decreased in the unconventional arm: RR 0.21 (95% CI 0.07 to 0.64, P = 0.007) (I 2 = 0%, P = 0.62). There was no significant heterogeneity (START A 2008; START B 2008) (Analysis 1.8).
Late radiation toxicity 1. Late skin toxicity: skin toxicity at five years (Whelan 2002) was assessed using the Radiation Oncology Group/EORTC late radiation morbidity scale (Winchester 1992), which has a fivepoint scale (see additional Table 2 ). No woman had severe (Grade 4) skin toxicity: RR 0.99 (95% CI 0.44 to 2.22, P = 0.98). A test for heterogeneity was not applicable with only one trial. At five years 3% in both the experimental and control arms had moderate/severe skin toxicity. Whelan 2002 reported at 10 years, that 6% of those in the unconventional arm had moderate/severe late skin toxicity versus 3% in the conventional arm "no differences detected", no P value given, figures from text) (Whelan 2002).
2. Late radiation subcutaneous toxicity at five years: RR 1.00 (95% CI 0.81 to 1.24, P = 0.99). There was no heterogeneity (I 2 = 36%, P = 0.21) (Owen 2006; Whelan 2002) (Analysis 1.10). Late radiation subcutaneous toxicity at 10 years: moderate/severe subcutaneous toxicity was reported for 8% in the unconventionally fractionated arm, versus 4% in the conventional fractionation arm ("no differences detected", no P value given) (Whelan 2002).
3. Ischaemic heart disease (in women with left-sided tumours): RR 1.07 (95% CI 0.32 to 3.56, P = 0.91). There was no heterogeneity (I 2 = 0%, P = 0.47) (Analysis 
Cancer specific mortality
No data.
Relapse-free survival
Data available for Whelan 2002 at five years: RR 1.10 (95% CI 0.81 to 1.49, P = 0.37).
Mastectomy rate
Quality of life (trial-specific instruments)
Costs (to women and health services)
D I S C U S S I O N
For women with early breast cancer, achieving and maintaining local control in addition to maximising survival are the main goals of management. Whilst conservative surgery followed by radiation therapy allows preservation of the breast, the requirement for five to six weeks of radiation therapy, which may only be available at some distance from the woman's residence, can be a burden. The many costs involved (monetary and other) may mean that women choose mastectomy over breast conserving therapy to avoid the necessity for radiation therapy (Nattinger 2001).
Shortening the duration of postoperative breast radiation would provide the advantage of shorter disruption of normal activities and less time away from home and family. Reducing the number of fractions required would also free up radiation therapy machine time. This may reduce waiting lists and improve timely access to radiation therapy for other patients with cancer. The ability to reduce the number of fractions required to treat women with early breast cancer safely may, therefore, result in many benefits at a personal, national and international level provided acceptable local control, toxicity and survival can be maintained with this approach.
This review set out to explore whether shortened (altered fractionation) regimens used to treat women who have had conservative surgery for early breast cancer can offer the same tumour control and cosmetic results as longer fractionation regimens. We have been able to include data from four randomised controlled trials that compared different fractionation schemes. The comparison studied is altered fractionation (fraction size greater than 2 Gy) versus conventional fractionation (2 Gy per fraction).
Local control
For these comparisons, there appears to be no difference between the fractionation techniques for local control:
1. At five years, when the data from the authors is used: RR 0.93 (95% CI 0.73 to 1.19, P = 0.55) (Analysis 1.1), when data are extracted from the paper: RR 0.97 (95% CI 0.76 to 1.22, P = 0.78) (Analysis 1.2) and hazard ratio 0.93 (95% CI 0.63 to 1.38, P = 0.72) (Analysis 1.3).
2. At 10 years: RR 0.99 (95% CI 0.77 to 1.29, P = 0.96) (Analysis 1.4). For overall survival, there was no significant difference between the techniques: RR 0.89 (95% CI 0.77 to 1.04, P = 0.16) (Analysis 1.6). The use of unconventional fractionation was associated with significantly decreased acute radiation skin toxicity: RR 0.21 (95% CI 0.07 to 0.64, P = 0.007) (Analysis 1.8). There was no significant difference between the techniques for late skin toxicity, late subcutaneous toxicity, ischaemic heart disease or rib fractures. No data were available for costs, quality of life or women's preference. There are limitations related to assessment of subjective outcomes, such as cosmesis and breast induration, but this was well- The findings of this review provide reassurance that the practice of offering shortened radiation fractionation regimens to carefully selected groups of patients is unlikely to be detrimental in terms of local control, breast appearance, survival or late radiation breast toxicity. However, there are some caveats.
Breast appearance (cosmesis)
(1) These results are mostly applicable to women with small to medium breasts, aged greater than 50 years, with node negative tumours less than 3 cm in size, with negative pathological margins. is not adequate to detect differences in breast cancer mortality. If, however, there are truly no differences in local recurrence or late toxicity (e.g. cardiac morbidity) one would not expect to see differences in mortality. Late effects of radiation therapy, e.g. skin toxicity and subcutaneous induration (which may be detrimental to cosmesis) increase with time. This increase in both skin toxicity and subcutaneous toxicity was reported by Whelan 2002, who showed that late skin toxicity doubled (6% versus 3%) and late subcutaneous toxicity (8% versus 4%) was increased with longer follow up. Follow up in the studies for cosmetic outcomes varied in length. For Owen 2006, 63% have 5-year follow up and 11% have 10-year follow up for late change in breast appearance. For START A 2008 and START B 2008 it is not specified how many of the women photographically assessed for late change in breast appearance were followed for five years. All women assessed in Whelan 2002 had five years of follow up. With longer follow up for the remainder of the cohorts, we may see increased late radiation toxicity with potential detriment to cosmesis. In total, 271 local recurrences at five years were reported in 7095 women. The Owen 2006 study was not powered to detect significant differences in local recurrence. Using an alpha/beta ratio of 4 for breast tumour cells (Fowler 1989; Steel 1987; Williams 1985) allows conversion of radiation doses to a common biological equivalent dose (BED) (Fowler 1989; Steel 1997) . When the altered fractionation regime radiation doses are converted to BED (see Table 7 ), it is clear that the unconventional regimens (39 Gy in 13 fractions, 42.5 Gy in 13 fractions, 41. showed that all women irrespective of age showed improved local control with addition of a 16 Gy boost to conventionally fractionated radiotherapy. The reason for the lack of a difference in local control with lower BED used in the altered fractionation trials is uncertain. Possible reasons include inadequate follow up so far or the impact of the boost used in 47% of women treated (see Table  4 ). For START A 2008 and START B 2008, the use of a boost was roughly equally divided between the treatment arms. While boosts are associated with decreased local recurrence, they are also associated with poorer cosmesis (Bartelink 2007). It has not been possible at this time to answer questions of cost, quality of life and patient preferences within this review. There was significantly less acute radiation toxicity in the unconventional arm and one could reasonably expect that shorter regimens are more readily tolerated and, therefore, would enhance quality of life for women. , two novel altered fractionation schedules were tested, however we were not able to analyse them separately to see if one was superior to the other. In addition, new techniques, such as accelerated partial breast irradiation, shorten treatment time even more by using larger fraction sizes to a smaller volume of breast tissue. These techniques are the subject of a number of ongoing trials. (5) New technology, for example, intensity modulated radiation therapy (IMRT), which uses multiple radiation beams in order to make treatment highly conformal (thus reducing dose to normal structures) and improve dose distribution has been shown to decrease acute radiotherapy toxicity (Donovan 2007) and improve cosmesis (Pignol 2008).
A U T H O R S ' C O N C L U S I O N S Implications for practice
In selected women with early breast cancer (node negative tumours with negative margins and size 3 cm or less) shortened fractionation regimens may be considered if the breast is of small to medium size. Longer follow up is required to obtain a full assessment of the impact of altered fractionation on local recurrence rates, cosmesis and other toxicity.
Implications for research
There are a number of questions still unanswered that relate to the use of altered fraction size in the treatment of early breast cancer for women undergoing breast cancer surgery.
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R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Owen 2006
Methods Randomised, multi-centre setting: tertiary cancer centres Participants 1410 British women with operable (T1-3N0-1MO) invasive breast cancer requiring radiotherapy. 1138 women had small or medium breasts (from photographs at baseline) . Median follow up 9.7 years (range 7.8 to 11.8). Secondary outcomes: disease-free survival, overall survival, second primaries, health economics consequences (not specified) and toxicity. Women reviewed annually for locoregional relapse and normal tissue effects Notes Normal tissue effects assessed by photos, patient and doctor assessments. Photos at baseline, 2 and 5 years (blinded assessment)
Risk of bias
Bias
Authors' judgement Support for judgement
Adequate sequence generation? Low risk Quote: "randomly assigned" (Abstract) . Quote: "computer generated and not blinded" (Abstract). Quote: "START A patients were randomised" (Para 3, page 3 Unclear risk Cosmetic outcome, late radiation toxicity and quality of life: Quote: "1129/2236 enrolled in quality of life study" It is not clear how the patients enrolled in the quality of life study were selected 1306/2236 enrolled in photographic study: assessed in 1055 patients with both a baseline and a follow-up photograph Quote: "There were no associations between score for change in breast appearance (photographic) at two years or patient demographic or treatment characteristics and
whether or not the patient had a five-year assessment (data not shown)." It is not clear why not all patients were enrolled in the photographic study
Incomplete outcome data addressed? Objective outcomes
Low risk Attrition described clearly: Quote: "41.6 Gy in 13 fractions; 2 with baseline data only, 1 moved, 1 unknown, 39 Gy in 13 fractions; 2 with baseline data only, 2 withdrew consent to follow up after randomisation, 50 Gy in 25 fractions; 5 with baseline data only, 3 withdrew consent to follow up after randomisation, 2 moved"
Free of selective reporting? Unclear risk Outcomes specified in methods/protocol: local-regional tumour relapse, late normal tissue effects (photographic change in breast appearance). Quality of life, disease-free survival, overall survival, second primary cancers, health economic consequences, ischaemic heart disease, symptomatic rib fracture, symptomatic lung fibrosis, brachial plexopathy Outcomes reported in paper: local-regional tumour relapse, distant relapse,disease-free survival, overall survival, second primary cancers, ischaemic heart disease, symptomatic rib fracture, symptomatic lung fibrosis, brachial plexopathy, disease-free survival, overall survival, second primary cancers, ischaemic heart disease, symptomatic rib fracture, symptomatic lung fibrosis, brachial plexopathy "Quality of life outcomes will be the subject of another paper". Health economic consequences not reported Primary outcome: loco-regional relapse, normal tissue effects and quality of life. Secondary outcomes: disease-free survival, overall survival, second primaries, health economics consequences (not specified) and toxicity. Women reviewed annually for locoregional relapse and normal tissue effects Notes Normal tissue effects assessed by photos, patient and doctor assessments. Photos at baseline, 2 and 5 years (blinded assessment)
Risk of bias
Bias
Authors' judgement Support for judgement
Adequate sequence generation? Low risk Quote: "randomly assigned" (Abstract) . Quote: "computer generated and not blinded" (Abstract). Quote: "START B patients were randomised" (Para 2, page 2).
Probably done
Allocation concealment? Low risk Quote: "Randomisation was arranged via telephone at the Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTSU), Sutton, UK, where the patient details were recorded and treatment allocated. Randomisation was not blinded. Computer-generated permuted blocks were used as a method of allocation" (Para 2, page 2) Provided those undertaking recruitment are not aware that permuted blocks are being used, or the block size, then this should not distort the recruitment 
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